RPRX Royalty Pharma PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: RPRX
- PE Ratio
The price-to-earnings ratio for Royalty Pharma stock stands at 13.66 as of Jun 5, 2025. This is based on the current EPS of $2.47 and the stock price of $33.75 per share. The current PE ratio is comparable to the past four-quarter average.
RPRX PE ratio history
Over the last five years, the average PE ratio of Royalty Pharma has been 49.03. The current 13.66 P/E ratio is 72% lower than the historical average. In the past five years, RPRX's PE ratio peaked in the Dec 2022 quarter at 395.2, with a price of $39.52 and an EPS of $0.1. The Sep 2024 quarter marked the lowest point at 11.01, with a price of $28.29 and an EPS of $2.57.
Royalty Pharma PE ratio by year
Maximum annual increase: 1,377.94% in 2022
Maximum annual decrease: -97.2% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 13.29 | 20.16% | $25.51 | $1.92 |
| 2023 | 11.06 | -97.2% | $28.09 | $2.54 |
| 2022 | 395.2 | 1,377.94% | $39.52 | $0.1 |
| 2021 | 26.74 | -29.48% | $39.85 | $1.49 |
| 2020 | 37.92 | N/A | $50.05 | $1.32 |
| 2019 | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A |
Royalty Pharma PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 12.6 | -5.19% | $31.13 | $2.47 |
| Dec 2024 | 13.29 | 20.71% | $25.51 | $1.92 |
| Sep 2024 | 11.01 | -36.94% | $28.29 | $2.57 |
| Jun 2024 | 17.46 | 2.89% | $26.37 | $1.51 |
| Mar 2024 | 16.97 | 53.44% | $30.37 | $1.79 |
| Dec 2023 | 11.06 | -84.11% | $28.09 | $2.54 |
| Sep 2023 | 69.59 | 24.51% | $27.14 | $0.39 |
| Jun 2023 | 55.89 | 14.79% | $30.74 | $0.55 |
| Mar 2023 | 48.69 | -87.68% | $36.03 | $0.74 |
| Dec 2022 | 395.2 | 1,021.13% | $39.52 | $0.1 |
| Sep 2022 | 35.25 | -11.12% | $40.18 | $1.14 |
| Jun 2022 | 39.66 | 46.56% | $42.04 | $1.06 |
| Mar 2022 | 27.06 | 1.2% | $38.96 | $1.44 |
| Dec 2021 | 26.74 | 43.53% | $39.85 | $1.49 |
| Sep 2021 | 18.63 | 13.18% | $36.14 | $1.94 |
RPRX Price vs fair value
RPRX average PE ratio chart
Currently, RPRX's PE ratio is lower than the 3-year average.
RPRX PE vs peers
RPRX's PE ratio stands lower than its peer stocks LLY and ABT.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RPRX Royalty Pharma plc | 13.67 | $18.99B |
| ABT Abbott Laboratories | 17.35 | $233.05B |
| LLY ELI LILLY & Co | 62.13 | $726.63B |
| ANIP Ani Pharmaceuticals Inc | N/A | $1.32B |
Frequently asked questions
What is Royalty Pharma's PE ratio?
The price to earnings ratio for RPRX stock as of Jun 5, 2025, stands at 13.66.
What is the 3-year average PE ratio for Royalty Pharma (RPRX)?
The 3-year average price to earnings ratio for RPRX stock is 60.56.
What is the highest PE ratio for RPRX?
The highest quarterly PE ratio in the last five years has been 395.2 and it was in the Dec 2022 quarter.
How does the current PE ratio for RPRX compare to its historical average?
RPRX's current price to earnings ratio is 72% below its 5-year historical average.
How is RPRX's PE ratio calculated (Royalty Pharma PE ratio formula)?
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Jun 5, 2025), Royalty Pharma's stock price is $33.75. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $2.47. Therefore, Royalty Pharma's PE ratio for today is 13.66. PE RATIO(13.66) = STOCK PRICE($33.75) / TTM EPS($2.47)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.